Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. Issue 9 (19th July 2013)

• Record Type: Journal Article
• Authors: Gattelli, Albana; Nalvarte, Ivan; Boulay, Anne; Roloff, Tim C.; Schreiber, Martin; Carragher, Neil; Macleod, Kenneth K.; Schlederer, Michaela; Lienhard, Susanne; Kenner, Lukas; Torres‐Arzayus, Maria I.; Hynes, Nancy E.
• Is Part Of: EMBO molecular medicine. Volume 5:Issue 9(2013:Sep.)
• Page Start: 1335
• Page End: 1350
• Publication Date: 2013-07-19
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.1002/emmm.201302625
• Languages: English
• ISSNs: 1757-4676

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="emmm201302625-sec-0001" sec-type="section"> <p>We show that elevated levels of Ret receptor are found in different sub‐types of human breast cancers and that high Ret correlates with decreased metastasis‐free survival. The role of Ret in ER+ breast cancer models was explored combining <italic>in vitro</italic> and <italic>in vivo</italic> approaches. Our analyses revealed that ligand‐induced Ret activation: (i) stimulates migration of breast cancer cells; (ii) rescues cells from anti‐proliferative effects of endocrine treatment and (iii) stimulates expression of cytokines in the presence of endocrine agents. Indeed, we uncovered a positive feed‐forward loop between the inflammatory cytokine IL6 and Ret that links them at the expression and the functional level. <italic>In vivo</italic> inhibition of Ret in a metastatic breast cancer model inhibits tumour outgrowth and metastatic potential. Ret inhibition blocks the feed‐forward loop by down‐regulating Ret levels, as well as decreasing activity of Fak, an integrator of IL6‐Ret signalling. Our results suggest that Ret kinase should be considered as a novel therapeutic target in subsets of breast cancer.</p> </sec> </abstract>